Zhone Technologies (NASDAQ:ZHNE) issued its quarterly earnings data on Tuesday. The company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01, American Banking News reports. The company had revenue of $28.60 million for the quarter, compared to the consensus estimate of $29.25 million. Zhone Technologies Inc (NASDAQ:ZHNE), net profit margin is 3.60% and weekly performance is -14.57%. On last trading day company shares ended up $3.05. Analysts mean target price for the company is $6.00. Zhone Technologies Inc (NASDAQ:ZHNE), distance from 50-day simple moving average (SMA50) is -0.61%.
Equities researchers at Morgan Stanley began coverage on shares of ImmunoGen, Inc. (NASDAQ:IMGN), in a research report issued on Wednesday. The firm set an “underweight” rating and a $10.00 price target on the stock. Morgan Stanley’s price objective suggests a potential downside of 23.78% from the stock’s previous close. ImmunoGen, Inc. (NASDAQ:IMGN), fell 8.23% in last trading session and ended the day on $12.03. IMGN, return on assets is -38.90%. ImmunoGen, Inc. (NASDAQ:IMGN), quarterly performance is -17.98%.
Prothena Corporation PLC (NASDAQ:PRTA)’s shares dropped 4.62% to $22.04. The company on June 25 announced that it has priced an underwritten public offering of 4,750,000 of its ordinary shares at a price to the public of $22.50 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares in the offering are to be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 712,500 ordinary shares. Prothena Corporation PLC (NASDAQ:PRTA), shares moved down 5.28% in last trading session and was closed at $21.89, while trading in range of $21.76 – 22.83. Prothena Corporation PLC (NASDAQ:PRTA), year to date (YTD) performance is -17.46%.
Shares of Oncothyreon Inc (USA) (NASDAQ:ONTY), jumped up 3.4% on Monday after the company declared that it has moved into a partnership deal with Celldex Therapeutics, Inc., (CLDX). Both the firms would join hands on a joint clinical trial of ONT-10 and varlilumab (CDX-1127). The phase Ib trial would be an open label study, wherein ONT-10 will be administered at the recommended single agent dose in combination with varlilumab at two dose levels in patients suffering from advanced breast or ovarian cancer. Oncothyreon Inc (USA) (NASDAQ:ONTY), ended the last trading day at $3.28. Company weekly volatility is calculated as 5.47% and price to cash ratio as 3.96. Oncothyreon Inc (USA) (NASDAQ:ONTY), showed a negative weekly performance of 4.37%.
Xplore Technologies Corp. (NASDAQ:XPLR), a developer of mobile wireless tablet PC computing systems, reported fiscal 2014 net loss of $1.76 million, compared to a net income of $306 thousand in the prior year. Xplore Technologies Corp. (NASDAQ:XPLR), net profit margin is -1.70% and weekly performance is -8.04%. On last trading day company shares ended up $5.72. Xplore Technologies Corp. (NASDAQ:XPLR), distance from 50-day simple moving average (SMA50) is -3.04%.